Journey Medical (DERM) Operating Income (2020 - 2026)

Journey Medical has reported Operating Income for 7 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 55.11% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$6.3 million (up 8.26% YoY), and the FY2025 full-year result was -$8.2 million, up 40.25% from the prior year.
• Operating Income for Q1 2026 stood at -$1.5 million, down from -$443000.0 in the prior quarter.
• The five-year high for Operating Income was $17.2 million in Q3 2023, with the low at -$10.1 million in Q1 2024.
• Historically, Operating Income has averaged -$3.1 million across 5 years, with a median of -$2.9 million in 2024.
• The largest YoY upside for Operating Income was 281.68% in 2023 against a maximum downside of 976.69% in 2023.
• Journey Medical's Operating Income stood at -$10.0 million in 2022, then surged by 78.95% to -$2.1 million in 2023, then jumped by 206.18% to $2.2 million in 2024, then slumped by 119.83% to -$443000.0 in 2025, then plunged by 236.79% to -$1.5 million in 2026.
• The last three Operating Income figures came in at -$1.5 million (Q1 2026), -$443000.0 (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.